GlassScriptPhysician profile
Collis L Barksdale
NPI 1316999709
$3,519.87
in general payments reported to CMS, 2019-2025
34 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $678 · 2020: $622 · 2021: $939 · 2022: $688 · 2023: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $592 · Education: $0.79.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $592.28 |
| Education | $0.79 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $419.83 | 2019-2023 | Mounjaro, Trulicity, Jardiance |
| Novo Nordisk INC | $359.80 | 2019-2022 | |
| Abbvie INC. | $303.25 | 2019-2023 | Vraylar, Qulipta |
| Pfizer INC. | $294.00 | 2019-2023 | |
| Abbott Laboratories | $214.70 | 2021-2023 | Freestyle Libre 3, Freestyle Libre 2 |
| Astrazeneca Pharmaceuticals LP | $209.69 | 2019-2022 | |
| Antares Pharma, INC. | $162.83 | 2019-2023 | Nocdurna, Xyosted, Tlando |
| Janssen Pharmaceuticals, INC | $161.90 | 2020-2022 | |
| Glaxosmithkline, LLC. | $155.90 | 2019-2023 | Trelegy Ellipta, Shingrix |
| Astellas Pharma US INC | $118.04 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $113.66 | 2021-2023 | |
| Dexcom, INC. | $108.93 | 2021-2023 | Dexcom G6 Transmitter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $106.36 | 2019-2021 | |
| Amgen INC. | $97.20 | 2019-2023 | Repatha, Otezla |
| Sanofi-Aventis U.S. LLC | $85.12 | 2019-2021 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amarin Pharma, INC. | $69.59 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $69.35 | 2022 | |
| Merck Sharp & Dohme LLC | $66.12 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $53.75 | 2019-2020 | |
| Eisai INC. | $46.84 | 2021-2022 | |
| Allergan, INC. | $43.86 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $40.06 | 2019-2022 | |
| Daiichi Sankyo INC. | $33.44 | 2019-2023 | Injectafer |
| Arbor Pharmaceuticals, INC. | $31.38 | 2019-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $23.46 | 2019 | |
| Halozyme INC | $22.90 | 2023 | |
| Sunovion Pharmaceuticals INC. | $17.96 | 2022 | |
| Esperion Therapeutics, INC. | $17.92 | 2021 | |
| Hikma Pharmaceuticals USA | $17.59 | 2022 | |
| Exact Sciences Corporation | $14.78 | 2023 | Cologuard Collection Kit |
| Lundbeck LLC | $14.27 | 2023 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $13.37 | 2019 | |
| Mannkind Corporation | $11.23 | 2019 | |
| Sumitomo Pharma America, INC. | $0.79 | 2023 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Collis Barksdale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.